王鹏飞

发布时间：2021-07-09浏览次数：12160

教师基本信息

姓名：王鹏飞(Pengfei Wang)

职称：正高

职务：青年研究员(Junior Professor)

电子邮箱：pengfei_wang@fudan.edu.cn

办公地点：复旦大学江湾校区生命科学学院E501-4

个人网页/课题组主页：https://scholar.google.com/citations?user=fWjlGn8AAAAJ&hl=en

研究方向：

抗病毒药物和疫苗

Antiviral therapeutics and vaccines

个人简介：

王鹏飞，2006-2010年就读于北京师范大学获得学士学位；2010-2015年就读于复旦大学生命科学学院并获得博士学位； 2015-2019年于美国洛克菲勒大学从事博士后研究；2020-2021年任美国哥伦比亚大学助理研究员，2021年7月起任复旦大学生命科学学院青年研究员、博士生导师。入选科睿唯安（Clarivate）2023年度“全球高被引科学家”和爱思维尔（Elsevier）“2023全球前2%顶尖科学家榜单”；被聘为复旦大学首届“小米青年学者”；曾获“上海科技青年引领35人计划”提名奖、阿里巴巴达摩院“青橙优秀入围奖”等。长期从事新发传染病防治方面的研究，包括针对病毒的抗体和药物筛选、疫苗评估等。至今发表论文60多篇；累计引用9000余次；其中以（共同）第一或通讯作者身份在Nature (3篇)、Nat. Rev. Immun.、Cell Host & Microbe (3篇)、Cell Discovery (3篇)、Proc. Natl. Acad. Sci. U.S.A.等期刊发表论文20多篇。

Pengfei Wang is a Junior Professor and PhD supervisor at Fudan University. From 2006 to 2010, he studied at Beijing Normal University, where he obtained his bachelor's degree. He then pursued his doctoral studies at the School of Life Sciences, Fudan University from 2010 to 2015. From 2015 to 2019, he carried out postdoctoral research at Rockefeller University in the United States. He served as an Associate Researcher Scientist at Columbia University from 2020 to 2021. Starting in July 2021, he assumed the position of Junior Professor at the School of Life Sciences, Fudan University.

Dr. Wang has been listed in Clarivate’s “Highly Cited Researcher 2023” and Elsevier/Stanford’s “World's Top 2% Scientists 2023”. He has been honored with awards such as the nomination for the "2022 Shanghai Science & Technology 35 under 35" and the outstanding candidate award of 2022 Alibaba DAMO Academy Young Fellow. He has been deeply involved in research related to the prevention and treatment of emerging infectious diseases, including the screening of antibodies and drugs against viruses, vaccine evaluation, and functional cure research for HIV/AIDS.

To date, he has published over 60 papers, which have been cited more than 9,000 times. Of these, over 20 were published in leading journals such as Nature (3), Nat. Rev. Immun., Cell Host & Microbe (3), Cell Discovery (3), and Proc. Natl. Acad. Sci. U.S.A., where he served as the (co-)first author or corresponding author.

授课情况：

感染与免疫（H）

Infection & Immunology（H）

招生专业：

遗传学(Genetics)、微生物学(Microbiology)、免疫学(Immunology)

科研项目：

科技部重点研发、国自然面上项目等

National Key Research and Development Program of China, National Natural Science Foundation of China

获奖情况：

科睿唯安（Clarivate）2023年度“全球高被引科学家”、爱思维尔（Elsevier）“2023全球前2%顶尖科学家榜单”

World's Top 2% Scientists 2023 (Elsevier/Stanford)

- Clarivate Highly Cited Researcher 2023

代表性论文和论著：

  1. Wang X, Jiang S, Ma W, Li X, Wei K, Xie F, Zhao C, Zhao X, Wang S, Li C, Qiao R, Cui Y, Chen Y, Li J, Cai G, Liu C, Yu J, Li J, Hu Z, Zhang W, Jiang S, Li M#, Zhang Y#, Wang P#. Enhanced neutralization of SARS-CoV-2 variant BA.2.86 and XBB sub-lineages by a tetravalent COVID-19 vaccine booster.  Cell Host & Microbe, 2023, DOI: 10.1016/j.chom.2023.11.012.

  2. Wang X, Jiang S, Jiang S, Li X, Ai J, Lin K, Lv S, Zhang S, Li M, Li J#, Dai L#, Hu Z#, Zhang W#, Zhang Y#, Wang P#. Neutralization of SARS-CoV-2 BQ.1.1, CH.1.1, and XBB.1.5 by Breakthrough Infection Sera from Previous and Recent Waves in China. Cell Discovery, 2023, 9(1):64.

  3. Wang X, He X, Jiang S, Fu Z, Jiang S, Zhao X, Zhao C, Li Y, Li D, Zhang W, Ai J#, Zhang Y#, Xu C#, Wang P#. Limited enhancement of antibody and B-cell responses to prototype booster vaccination following SARS-CoV-2 Delta breakthrough infection. Journal of Medical Virology. 2023; 95(2): e28540.

  4. Chen Y, Zhao X, Zhou H, Zhu H, Jiang S#, Wang P#. Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses. Nature reviews immunology. 2023,23, 189–199.

  5. Wang H, Xue Q, Zhang H, Yuan G, Wang X, Sheng K, Li C, Cai J, Sun Y, Zhao J, Lu J, Fang S, Yang Y, Zhang Y, Huang Y, Wang J, Xu JH, Jiang MX, Wang X, Shen L, Liu Y, Liu Q, Zhang Q, Wang S, Wang P#, Qiu C#, Ai J#, Zhang W. Neutralization against Omicron subvariants after BA.5/BF.7 breakthrough infection weakened as virus evolution and aging despite repeated prototype-based vaccination. Emerging Microbes & Infections. 2023,5:2249121.

  6. Qiao R, Tang W, Li J, Li C, Zhao C, Wang X, Li M, Cui Y, Chen Y, Cai G, Wu Q, Zhao X#, Wang P#. Structure-based virtual screening of ROCK1 inhibitors for the discovery of Enterovirus-A71 antivirals. Virology. 2023, 585:205-14.

  7. Wang X, Li M, Lu P, Li C, Zhao C, Zhao X, Qiao R, Cui Y, Chen Y, Li J, Cai G, Wang P#. In Vitro Antibody-Dependent Enhancement of SARS-CoV-2 Infection Could Be Abolished by Adding Human IgG. Pathogens. 2023, 30;12(9):1108.

  8. Ai J, Wang X, He X, Zhao X, Zhang Y, Jiang Y, Li M, Cui Y, Chen Y, Qiao R, Li L, Yang L, Li Y, Hu Z#, Zhang W#, Wang P#. Antibody evasion of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2 and BA.3 sub-lineages. Cell Host & Microbe, 2022, 10;30(8):1077-1083.e4.

  9. Wang X, Ai J, Li X, Zhao X, Wu J, Zhang H, He X, Zhao C, Qiao R, Li M, Cui Y, Hu Z#, Xu C#, Zhang W#, Wang P#. Neutralization of Omicron BA.4/BA.5 and BA.2.75 by Booster Vaccination or BA.2 Breakthrough Infection Sera. Cell Discovery, 2022. doi: 10.1038/s41421-022-00472-5.

  10. Wang X, Zhao X, Song J, Wu J, Zhu Y, Li M, Cui Y, Chen Y, Yang L, Liu J, Zhu H, Jiang S, Wang P#. Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies. Emerging Microbes & Infections. 2022;11(1):477-481.

  11. Zhao X, Li C, Chiu MC, Qiao R, Jiang S, Wang P#, Zhou J#. Rock1 is a novel host dependency factor of human enterovirus A71: implication as a drug target. Journal of Medical Virology. 2022. doi: 10.1002/jmv.27975.

  12. Wang X, Zhao X, Cui Y, Qiao R, Li M, Chen Y, Yang L, Jiang S, Wang P#. Neutralization of distinct Omicron sublineages by longitudinal vaccination sera. Journal of Medical Virology 2022. doi: 10.1002/jmv.28017.

  13. Wang P*, Nair MS*, Liu L*, Iketani S*, Luo Y, Guo Y, Wang M, Yu J, Zhang B, Kwong PD, Graham BS, Mascola JR, Chang JY, Yin MT, Sobieszczyk M, Kyratsous CA, Shapiro L, Sheng Z, Huang Y, Ho DD. Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7. Nature. 2021, 593, 130–135.

  14. Wang P*#, Casner RG*, Nair MS*, Wang M, Yu J, Cerutti G, Liu L, Kwong PD, Huang Y, Shapiro L#, Ho DD#. Increased Resistance of SARS-CoV-2 Variant P.1 to Antibody Neutralization. Cell Host & Microbe, 2021, 29 (5), 747-751. e4.

  15. Liu L*, Wang P*(Equal contribution), Nair MS*, Yu J*, Rapp MA*, Wang Q*, Luo Y, Sahi V, Figueroa A, Guo XV, Cerutti G, Bimela J, Gorman J, Zhou T, Kwong PD, Sodroski JG, Yin MT, Sheng Z, Huang Y, Shapiro L, Ho DD. Potent Neutralizing Monoclonal Antibodies Directed to Multiple Epitopes on the SARS-CoV-2 Spike. Nature, 2020, 584, 450–456.

  16. Han Y*, Duan X*, Yang L*, Nilsson-Payant BE*, Wang P*(Equal contribution), Duan F*, Tang X*, Yaron TM*, Zhang T, Uhl S, Bram Y, Richardson C, Zhu J, Zhao Z, Redmond D, Houghton S, Nguyen D, Xu D, Wang X, Jessurun J, Borczuk A, Huang Y, Johnson JL, Liu Y, Xiang J, Wang H, Cantley LC, tenOever BR, Ho DD, Pan FC, Evans T, Chen HJ, Schwartz RE, Chen S. Identification of SARS-CoV-2 Inhibitors using Lung and Colonic Organoids. Nature. 2021, 589, 270–275.

  17. Wang P, Gajjar MR, Yu J, Padte NN, Gettie A, Blanchard JL, Russell-Lodrigue K, Liao LE, Perelson AS, Huang Y, Ho DD. Quantifying the contribution of Fc-mediated effector functions to the antiviral activity of anti-HIV-1 IgG1 antibodies in vivo. PNAS. 2020, 117(30):18002-18009.

  18. Wang P, Casner RG, Nair MS, Yu J, Guo Y, Wang M, Chan JF, Cerutti G, Iketani S, Liu L, Sheng Z, Chen Z, Yuen KY, Kwong PD, Huang Y, Shapiro L, Ho DD. A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses. Emerging Microbes & Infections. 2022, 11(1):147-157.

  19. Wang P*, Liu L*, Nair MS*, Yin MT*, Luo Y, Wang Q, Yuan T, Mori K, Solis AG, Yamashita M, Lawrence J. Purpura LJ, Laracy JC, Yu J, Sodroski JG, Huang Y, Ho DD. SARS-CoV-2 Neutralizing Antibody Responses Are More Robust in Patients with Severe Disease. Emerging Microbes & Infections. 2020, 9(1):2091-2093.

  20. Wang P. Anti-HIV Passive Immunization in Animal Models. Journal of HIV & Retro Virus. 2018, 4 (1): 4.

  21. Wang P, Lu P, Qu X, Shen Y, Zeng H, Zhu X, Zhu Y, Li X, Wu H, Xu J, Lu H, Ma Z, Zhu H. Reactivation of HIV-1 from Latency by an Ingenol Derivative from Euphorbia Kansui. Scientific Reports. 2017, 25;7(1):9451.

  22. Wang P, Qu X, Zhou X, Shen Y, Ji H, Fu Z, Deng J, Lu P, Yu W, Lu H, Zhu H. Two cellular microRNAs, miR-196b and miR-1290, contribute to HIV-1 latency. Virology. 2015, 486:228-38.

  23. Wang P, Qu X, Wang X, Zhu X, Zeng H, Chen H, Zhu H. Specific reactivation of latent HIV-1 with designer zinc-finger transcription factors targeting the HIV-1 5′-LTR promoter. Gene Therapy. 2014, 21(5):490-495.

  24. Wang P, Qu X, Wang X, Liu L, Zhu X, Zeng H, Zhu H. As2O3 synergistically reactivate latent HIV-1 by induction of NF-κB. Antiviral Research. 2013, 100 (3): 688-697.

  25. Qu X*, Wang P*(Equal contribution), Ding D, Li L, Wang H, Ma L, Zhou X, Liu S, Lin S, Wang X, Zhang G, Liu S, Liu L, Wang J, Zhang F, Lu D, Zhu H. Zinc-finger-nucleases mediate specific and efficient excision of HIV-1 proviral DNA from infected and latently infected human T cells. Nucleic Acids Research. 2013, 41 (16): 7771-7782.  

  26. Jiao Y*, Wang P*(Equal contribution), Zhang H, Zhang T, Zhang Y, Zhu H, Wu H. HIV-1 Co-Receptor Usage Based on V3 Loop Sequence Analysis: Preferential Suppression of CXCR4 Virus Post HAART? Immunological Investigations 2011, 40(6):597-613.